Posts

Image

EU Joint Clinical Assessment after the first reports: How should companies interpret the findings?

Image

England’s Single National Formulary: Win-Win Reform or New Market Access Bottleneck?

Image

Anti-Amyloid Drugs in Alzheimer’s: Breakthrough, Dead End, or Reimbursement Reality Check?

Image

MFN Pricing and the “Global Launch Freeze”: A More Measured Perspective

Image

NICE, VPAG and the UK’s new signal to pharma: Progress at last

Image

MASH in 2025: New Therapies, New Challenges

Image

China’s NRDL: The World’s Largest Market Access Event Is Underway